The FDA’s Leucovorin Approval—A Departure From Evidentiary Standards

This Viewpoint explores the US Food and Drug Administration’s plan to approve leucovorin for patients with autism and the potential implications for evidentiary standards.

Authors

Institutions

Publication Details

Journal
JAMA
Published
2025-12-22
DOI
https://doi.org/10.1001/jama.2025.24532
Primary Topic
Autism Spectrum Disorder Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The FDA’s Leucovorin Approval—A Departure From Evidentiary Standards

Daniel Aaron, Michael S. Sinha, I. Glenn Cohen
JAMA
Autism Spectrum Disorder Research
article

The FDA’s Leucovorin Approval—A Departure From Evidentiary Standards

Daniel Aaron, Michael S. Sinha, I. Glenn Cohen
article en

Abstract

This Viewpoint explores the US Food and Drug Administration’s plan to approve leucovorin for patients with autism and the potential implications for evidentiary standards.

JAMAVol. 335(5)
University of Utah (US), Harvard University Press (US), Saint Louis University (US)
Zero hunger
Openalex Percentile: Top 34%
Autism Spectrum Disorder Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The FDA’s Leucovorin Approval—A Departure From Evidentiary Standards — Daniel Aaron, Michael S. Sinha, et al. · JAMA (2025) | TGRS Research Map | TGRS